GlaxoSmithKline Pharmaceuticals Ltd on Monday reported a 16 per cent rise in consolidated net profit to ₹237.18 crore in the first quarter ended June 30, 2026.The company had posted a consolidated net profit of ₹205 crore in the corresponding period of the preceding financial year, GlaxoSmithKline Pharmaceuticals Ltd (GSK India) said in a regulatory filing.Consolidated revenue from operations in the first quarter of FY27 stood at ₹938.44 crore against ₹805.17 crore in the year-ago period, it added.Total expenses in Q1 FY27 increased to ₹659.75 crore, compared to ₹569.91 crore in the same period a year ago, the company said.The first quarter performance reflects continued progress in the company's portfolio transformation strategy, supplemented by execution excellence and a favourable base effect from the comparable period last year, GSK India said.Commenting on the performance, GSK India MD Bhushan Akshikar said,"GSK India's broad-based growth demonstrates the resilience of the core general medicines and vaccines portfolio and the growing contribution of the innovative business." This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development, he added.“With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India,” Akshikar said.Published on August 3, 2026